ArticleDiscover oncology2026
Disappearance of histone H3F3A mutation in metastatic giant cell tumor of bone during long term follow up.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant cell tumor of bone (GCTB) is a locally aggressive tumor that rarely metastasizes, although a small subset undergoes malignant transformation. H3F3A driver mutations have been recognized as characteristic molecular features of GCTB. We describe a case of a refractory GCTB with disappearance of the H3F3A mutation and that later developed a malignancy within the preexisting tumor. CASE PRESENTATION: A 22-year-old male was diagnosed with GCTB and underwent multiple surgeries for recurrence and lung metastases. The tumor relapsed in the knee, soft tissue, and lungs and required repeated resections. All relapsed tumor tissues were positive for H3F3A mutation. A large lung metastatic tumor developed 35 years after the initial surgery. The specimen from the last lung metastasis showed no significant changes in the morphology and characteristics of GCTB, despite the disappearance of the H3F3A mutation. Subsequently, liver and bone metastases appeared, and chemotherapy was initiated for presumed malignant transformation. Despite treatment, the disease progressed, and the patient died.
conclusionThe disappearance of the H3F3A mutation may be associated with malignant transformation in GCTB, whereas our findings suggest that it does not correspond to the tumor's morphological or biological characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.